CVInsight(R) Monitoring System Will Be Demonstrated on Site
PITTSBURGH, PA--(Marketwired - Feb 25, 2016) - InteloMed, Inc., an emerging leader and developer of informatics for advanced non-invasive patient monitoring, will be exhibiting the CVInsight® Patient Monitoring & Informatics System for assessing dialysis treatment tolerance at the Annual Dialysis Conference. The Annual Dialysis Conference (ADC) is described as the world's largest multi-disciplinary conference on dialysis. This year's conference is hosted in Seattle, Washington February 28 through March 1, 2016 at the Washington State Convention Center.
"The Annual Dialysis Conference is an important meeting for the dialysis community, and so we are extremely enthusiastic to demonstrate our unique CVInsight® Patient Monitoring and Informatics System to this important group of clinicians," stated Jill Schiaparelli, InteloMed President and CEO. "Our technology is the first in a new category of advanced non-invasive monitoring options and provides unprecedented insight on the dialysis patient and we are eager to share these exciting advancements in dialysis tolerance monitoring with clinical leaders."
Demonstrations of the CVInsight® Monitoring System will be available in the scientific expo hall at the Washington State Convention Center, in the InteloMed booth, number 219.
Providing an unprecedented level of physiologic insight, the CVInsight® Monitoring System is an easy-to-use multi-parameter system. It empowers clinicians with non-invasive, real-time, dynamic and actionable information about a patient's dialysis tolerance. Based on patented and proprietary algorithms, the system alerts clinical staff members, allowing them to intervene to avoid dialysis interruptions that can have such serious patient consequences.
The CVInsight® Patient Monitoring and Informatics System is FDA-cleared and CE-marked and has launched commercially.
InteloMed is redefining the standard of care in patient monitoring and informatics through its intelligent, multi-dimensional, non-invasive CVInsight® Platform.
The CVInsight® Platform provides real-time insights to inform clinical decisions in a variety of healthcare applications, including in-patient and out-patient facilities, clinics, medical facilities and sleep labs.
InteloMed is headquartered in Wexford, PA.
For more information, visit us at www.InteloMed.com.
About the Annual Dialysis Conference
The Annual Dialysis Conference: The Thirty-sixth Annual Conference on Dialysis, and Twenty-seventh Annual Symposium on Pediatric Dialysis are presented by the University of Missouri School of Medicine, Department of Medicine, Division of Nephrology; Continuing Medical Education; the University of Missouri Sinclair School of Nursing; and the Academy for Postgraduate Health Care Education. This conference convenes an international group of practitioners and researchers to discuss current developments in the field of dialysis. The conference is designed for health professionals involved in established dialysis programs, as well as those working in new and developing programs. Both researchers and clinicians will find sessions of interest to them. Extensive commercial exhibits give participants a chance to see for themselves what is new in PD and HD products and services. For more information, visit: www.annualdialysisconference.org
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.